ライフサイエンスコーパス: lactide

1 triblock polymers, where PLA stands for poly(lactide).

2 comprising poly(dodecyl acrylate)-block-poly(lactide).

3 and utilized in the polymerization of (rac)-lactide.

4 a change in the rate of polymerization of L-lactide.

5 during the ring-opening polymerization of L-lactide.

6 enyl isocyanate and the polymerization of DL-lactide.

7 as initiators for the polymerization of rac-lactide.

8 a cis-rich telechelic polyoctenamer with d,l-lactide.

9 tal-catalyzed ring-opening polymerization of lactide.

10 the catalyzed ring opening polymerization of lactide.

11 cles composed of l-lactide homopolymer and l-lactide/1,3-dioxolane (co)polymers loaded with quercetin

12 nthrax infection, was encapsulated in poly-L-lactide 100-kDa microspheres.

13 In migration, lactide, AA-BD and [AA-BD](2) were identified in ethanol

14 The use of poly-l-lactide acid-based bioresorbable scaffolds is limited in

15 ning polymerization of this macrolactone and lactide afforded an ABA triblock copolymer.

16 led anionic ring-opening copolymerization of lactide and a cyclic phosphate allowed PLA to be prepare

17 ted with a 10% copolymer solution of 50:50 L-lactide and epsilon-caprolactone were statically seeded

18 during the ring-opening polymerization of l-lactide and epsilon-caprolactone.

19 he controlled ring-opening polymerization of lactide and epsilon-caprolactone.

20 ymer scaffolds fabricated from copolymers of lactide and glycolide were adsorbed with collagen IV, fi

21 nd biodegradable PLGA (a random copolymer of lactide and glycolide) to form a nanofibrous non-woven s

22 t tissues were fabricated from copolymers of lactide and glycolide.

23 ormation pertaining to the polymerization of lactide and other cyclic esters by discrete metal alkoxi

24 Besides the low cost of lactide and THF, the sustainability of this new class of

25 omonomers including commercially available l-lactide and trimethylene carbonate produced novel copoly

26 1,4-dioxane-2,5-dione was synthesized from L-lactide and used as the dienophile to prepare spiro[6-me

27 are first order with respect to monomer (rac-lactide) and 1.56 order in catalyst.

28 or transforming meso-LA directly into poly(L-lactide) and D-LA.

29 ac-LA is kinetically polymerized into poly(L-lactide) and optically resolved D-LA, with a high stereo

30 ic multi-block copolymers composed of poly(l-lactide) and poly ethylene glycol/poly(-caprolactone), a

31 The stereocomplexation of isotactic poly(L-lactide) and poly(D-lactide) has led to improved propert

32 copolymers of clinically validated poly(D,L-lactide) and poly(ethylene glycol) (PEG-Dlink(m)-PDLLA)

33 ing around Ti-6Al-4V, poly(L-lactide-co-D,L,-lactide), and 303 stainless steel implants with surface

34 -opening of the cyclic esters L-lactide, rac-lactide, and 2,5-morpholinediones.

35 polymerization of rac-lactide, L-lactide, DL-lactide, and caprolactone, followed by their photophysic

36 generally applicable to many other lactones, lactides, anhydrides, epoxides, and heterocumulenes and

37 ion in the stereoselective polymerization of lactide are described.

38 the ring-opening polymerization (ROP) of rac-lactide are rare outside of Group 13.

39 ontrolled ring-opening polymerization of rac-lactide are reported.

40 erized l-lactide, whereas endo-6 preferred d-lactide as the substrate.

41 udies also showed that L(1)ZnOEt polymerizes lactide at a rate faster than any other Zn-containing sy

42 catalyze the ring-opening polymerization of lactide at elevated temperatures to give narrowly disper

43 r the polymerization of caprolactone and rac-lactide at room temperature.

44 rto unknown high activity for the ROP of rac-lactide at room temperature.

45 reocomplex micelles from a mixture of poly(L-lactide)-b-poly(acrylic acid) and poly(D-lactide)-b-poly

46 y(L-lactide)-b-poly(acrylic acid) and poly(D-lactide)-b-poly(acrylic acid) diblock copolymers in wate

47 trated by their use in the synthesis of poly(lactide)-b-poly(butenediol)-b-poly(lactide) triblock cop

48 FA coupled poly(l-lactide)-b-poly(ethylene glycol) (FA-PEG-PLLA) was synth

49 xidation state and its subsequent monomer (l-lactide, B-butyrolactone, or cyclohexene oxide) selectiv

50 te hydrogels, we show that the use of poly(L-lactide)-based nanoparticles with platelet morphology as

51 lyl/benzyl)oxy-6-(H/alkyl)-2-oxy-benzoate-co-lactide-based polymer library was designed and studied f

52 forms across a substantial range of minority lactide block volume fractions (f (L) = 0.25 - 0.33) sit

53 n-driven self-assembly (ROPI-CDSA) of poly-L-lactide-block-polyethylene glycol block copolymers into

54 llable lengths of both styrene carbonate and lactide blocks.

55 studies reveal a first-order dependence on [lactide], but with a significant induction period.

56 ion from a dynamic combinatorial library and lactide can be converted to (MeCHC(O)O)6 in >80% yield.

57 rned matrix based on acrylate-functionalized lactide-chain-extended star polyethylene glycol (SPELA)

58 e encapsulated SOD in biodegradable poly(D,L-lactide co-glycolide) nanoparticles (SOD-NPs) and tested

59 Poly (d,l-lactide co-glycolide, PLGA)-based NPs loaded with a near

60 ere derived from poly(ethyleneglycol)-b-poly(lactide)-co-poly(N(3)-alpha-epsilon-caprolactone) with a

61 ne serum albumin (BSA) in injectable poly(DL-lactide- co-glycolide) (PLGA) 50/50 cylindrical implants

62 We assessed healing around Ti-6Al-4V, poly(L-lactide-co-D,L,-lactide), and 303 stainless steel implan

63 fabricated with thiolated chitosan and poly(lactide-co-E-caprolactone) (PLACL) was designed to achie

64 , self-adhesive, shape-transformable poly (L-lactide-co-epsilon-caprolactone) (BSS-PLCL) that can be

65 days of culture in the presence of poly(D,L-lactide-co-epsilon-caprolactone) (PDLLCL), poly(ethylene

66 monstrate that the prevascularized poly (D,L-lactide-co-epsilon-caprolactone) scaffold maintains viab

67 cutaneously implanted, retrievable poly (D,L-lactide-co-epsilon-caprolactone) scaffold.

68 ctive MgSO(4) particles into a PLCL (poly (l-lactide-co-epsilon-caprolactone)) substrate using 3D pri

69 The coating consisted of absorbable poly-lactide-co-glycolic acid (PLGA) and crystalline sirolimu

70 tion of a US contrast agent composed of poly-lactide-co-glycolic acid polymeric (PLGA) microspheres (

71 rowth factor 7-loaded galactosylated poly(DL-lactide-co-glycolic acid) (FGF7-GAL-PLGA) particles; 26-

72 ) encapsulated in negatively charged poly(dl-lactide-co-glycolic acid) nanoparticles, is designed to

73 0 nm) and for NPs made of PEGylated poly-d,l-lactide-co-glycolide (PEG-PLGA, a biocompatible FDA-appr

74 Biocompatible poly lactide-co-glycolide (PLGA) nanoparticles containing enc

75 ctone (PCL), poly-D,L-lactide (PLA), or poly-lactide-co-glycolide (PLGA), and hydrophilic blocks of p

76 matory mediators, encapsulated into poly(d,l-lactide-co-glycolide acid) (PLGA), and coated with a fin

77 eded onto tubularised polyglycolic acid:poly(lactide-co-glycolide acid) scaffolds.

78 deslorelin or transferrin-conjugated poly-l-lactide-co-glycolide nanoparticles (PLGA-NPs) encapsulat

79 Using poly-lactide-co-glycolide scaffolds as cell carriers, we tran

80 en-conjugated NPs made of biodegradable poly(lactide-co-glycolide) (Ag-PLG) are similarly effective p

81 porated methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) (mPEG-PLGA) GRFT NPs.

82 this approach was evaluated by using 3D poly(lactide-co-glycolide) (PLAGA) sintered microsphere scaff

83 otein bovine serum albumin (BSA)-loaded poly(lactide-co-glycolide) (PLG) core and drug-free poly(d,l-

84 on was achieved via hydrolysis of 85:15 poly(lactide-co-glycolide) (PLG) films.

85 virus RNA replicons (pSINCP), cationic poly(lactide-co-glycolide) (PLG) microparticles for DNA deliv

86 ctive of this study was to determine if poly(lactide-co-glycolide) (PLG) nanoparticles (NPs) loaded w

87 Os required a bioartificial microporous poly(lactide-co-glycolide) (PLG) scaffold niche for successfu

88 nvestigated the surface modification of poly(lactide-co-glycolide) (PLG) scaffolds with polysaccharid

89 Matrices of poly(lactide-co-glycolide) (PLG) were loaded with plasmid, wh

90 ition 50:50 poly (DL-lactide) (PLA)/poly (DL-lactide-co-glycolide) (PLG) with an inherent viscosity o

91 Nanoparticles were formed from 50:50 poly(DL-lactide-co-glycolide) (PLG) with two molecular weights (

92 ng solvent-extrusion, we formulated poly(D,l-lactide-co-glycolide) (PLGA) 50/50 milli-cylinder implan

93 pH-responsive nanoparticle based on poly(D,L-lactide-co-glycolide) (PLGA) and chitosan (CHIT) for del

94 u forming implant formulations based on poly(lactide-co-glycolide) (PLGA) and N-Methyl-2-Pyrrolidone

95 Here, we produce poly(lactide-co-glycolide) (PLGA) based microparticles with v

96 long-acting formulations, specifically poly(lactide-co-glycolide) (PLGA) based systems, have been us

97 his approach, LNG was encapsulated in a poly(lactide-co-glycolide) (PLGA) core surrounded by a poly(l

98 Poly (lactide-co-glycolide) (PLGA) has been used for making in

99 Poly(lactide-co-glycolide) (PLGA) has been used in many injec

100 Poly(lactide-co-glycolide) (PLGA) has most often been employe

101 ticles, microparticles, implants of poly(D,l-lactide-co-glycolide) (PLGA) have been demonstrated for

102 injectable (LAI) formulations based on poly(lactide-co-glycolide) (PLGA) have been developed to deli

103 long-acting depot formulations based on poly(lactide-co-glycolide) (PLGA) have been used clinically s

104 The NS made using GA conjugated poly(lactide-co-glycolide) (PLGA) have shown non-competitive

105 duced to change the properties of a poly(d,l-lactide-co-glycolide) (PLGA) matrix, thereby altering th

106 Biodegradable poly(lactide-co-glycolide) (PLGA) microparticles have been us

107 In this study we prepared large porous poly(lactide-co-glycolide) (PLGA) microparticles of celecoxib

108 ology for prediction of the size of poly(D,L-lactide-co-glycolide) (PLGA) microparticles produced by

109 Naltrexone-loaded poly(lactide-co-glycolide) (PLGA) microparticles were prepare

110 Various ratios of cryo-ground poly (lactide-co-glycolide) (PLGA) nanofibres (CPN) were incor

111 t a subcutaneous injection of PEGylated poly(lactide-co-glycolide) (PLGA) nanoparticles containing au

112 Poly (dl-lactide-co-glycolide) (PLGA) nanoparticles of acerola, g

113 We show that VP5k-coated poly(lactide-co-glycolide) (PLGA) nanoparticles rapidly penet

114 to 50% in the group using biodegradable poly(lactide-co-glycolide) (PLGA) nonwoven nanofibrous membra

115 ophosphoryl Lipid A encapsulated in poly(d,l-lactide-co-glycolide) (PLGA) NPs were used as the vaccin

116 Nanoparticles composed of poly(lactide-co-glycolide) (PLGA) or diblock copolymers of PE

117 14 and different carbohydrates-modified poly(lactide-co-glycolide) (PLGA) or poly(lactide-coglycolide

118 used to encapsulate the MRI agent in a poly(lactide-co-glycolide) (PLGA) or polylactide-poly(ethylen

119 Poly(lactide-co-glycolide) (PLGA) polymers have been widely u

120 roved LAI products are formulated using poly(lactide-co-glycolide) (PLGA) polymers.

121 of parenteral formulations comprised of poly(lactide-co-glycolide) (PLGA) requires assays of the rele

122 In this study, poly(D,l-lactide-co-glycolide) (PLGA) was investigated for this a

123 mers, poly(epsilon-caprolactone) (PCL), poly(lactide-co-glycolide) (PLGA), and poly(ethylene vinyl ac

124 series of bioresorbable polymers, i.e., poly(lactide-co-glycolide) (PLGA), poly(lactic acid) (PLLA),

125 s) formulated from the copolymers of poly(DL-lactide-co-glycolide) (PLGA).

126 In this study, we used cationic lipid-poly(lactide-co-glycolide) acid (PLGA) hybrid nanoparticles a

127 (chitosan and lecithin) and synthetic (poly(lactide-co-glycolide) and Eudragit S100(R) (ES100)) poly

128 We use poly(lactide-co-glycolide) copolymer (PLGA) fiber microfilame

129 s elicited by a vaccine system based on poly(lactide-co-glycolide) micro- or nano-particles enveloped

130 tidylic acid) (polyIC) in biodegradable poly(lactide-co-glycolide) microparticles (MPs) designed to r

131 th either H7 or H7 incorporated into poly(DL-lactide-co-glycolide) microparticles (PLG:H7).

132 ovine serum albumin was encapsulated in poly(lactide-co-glycolide) microparticles and was administere

133 Poly(lactide-co-glycolide) microparticles approximately 1 mum

134 of either polystyrene or biodegradable poly(lactide-co-glycolide) microparticles bearing encephalito

135 Heparin-loaded biodegradable poly (D,L-lactide-co-glycolide) microparticles were prepared by sp

136 ated MAP in PBS and encapsulation in poly(DL-lactide-co-glycolide) microparticles.

137 0 to 500 microns ganciclovir-loaded poly(D,L-lactide-co-glycolide) microspheres control the progressi

138 d efficacy of negatively charged 500-nm poly(lactide-co-glycolide) nanoparticles encapsulating gliadi

139 h a collagen matrix, was added to a poly (DL-lactide-co-glycolide) polymer (PLG) and placed at orthot

140 y to nanoparticles formulated using poly(D,L lactide-co-glycolide) polymer.

141 , PTX was covalently conjugated to poly (D,L-lactide-co-glycolide) polymeric core by redox-sensitive

142 bioabsorbable nanofibrous membranes of poly(lactide-co-glycolide) were effective to reduce adhesions

143 oparticles were prepared with PLGA [poly(d,l-lactide-co-glycolide), 50:50, MW.

144 SOR-EMs were prepared with poly(d,l-lactide-co-glycolide), iron oxide nanoparticles, and sor

145 -printed patches composed of a blend of poly(lactide-co-glycolide), polycaprolactone, and 5-fluoroura

146 gradable and biocompatible polymer, poly(d,l-lactide-co-glycolide), was used to fabricate curcumin mi

147 orous scaffolds of biomineralized 85:15 poly(lactide-co-glycolide), which locally release vascular en

148 n of a cationic amphiphilic copolymer, poly (lactide-co-glycolide)-graft-polyethylenimine (PgP) and i

149 (density, >1g/ml) microspheres of 85:15 poly(lactide-co-glycolide).

150 we engineered a composite fibrin-PLGA [poly(lactide-co-glycolide)]-sintered microsphere scaffold for

151 Poly(L-lactide-co-glycolide)based devices loaded with VEGF were

152 thetic controlled-release biomaterials, poly(lactide-co-glycolide; PLGA) microparticles (MPs) encapsu

153 affords the synthesis of lactone rich poly(l-lactide-co-lactone) statistical copolymeric blocks, whil

154 uncoated or coated with a thin layer of poly(lactide-co-sigma-caprolactone) copolymer alone or contai

155 Poly(lactide-co-sigma-caprolactone) copolymer-coated stents p

156 v adsorbed onto the surface of cationic poly(lactide-coglycolide) (PLG) microparticles were shown to

157 tavirus VP6 DNA vaccine encapsulated in poly(lactide-coglycolide) (PLG) microparticles.

158 poration of peptides in bioadhesive poly(D,L-lactide-coglycolide) (PLGA) microparticles, the use of m

159 ound I nanoparticle (compound I-NP)] in poly(lactide-coglycolide) (PLGA) was developed that shows sus

160 Poly (D,L-lactide-coglycolide) nanocapsules (NC) were used to enca

161 In this study, i.v. administered poly(lactide-coglycolide) nanoparticles were internalized by

162 ogenic inhibitor, was encapsulated with poly(lactide-coglycolide) to form K5 nanoparticles (K5-NP).

163 ed poly(lactide-co-glycolide) (PLGA) or poly(lactide-coglycolide)-b-poly(ethylene glycol) (PLGA-PEG)

164 hrough self-assembly of a biodegradable poly(lactide-coglycolide)-b-poly(ethylene glycol) diblock cop

165 bility as the L:G ratio increases, i.e., the lactide content increases.

166 A bioabsorbable membrane of glycolide and lactide copolymer was sutured over the defect to maximiz

167 he synthesis of poly(styrene carbonate-block-lactide) copolymers.

168 ive and controlled polymerization of racemic lactide (D,L-LA) using an initiator prepared in situ fro

169 zation of several common monomers, including lactide, delta-valerolactone, epsilon-caprolactone, a cy

170 Polymerizations of this bifunctional lactide derivative were successfully carried out under r

171 periments reported here on a poly(isoprene-b-lactide) diblock copolymer melt.

172 mmetric low molar mass poly(isoprene)-b-poly(lactide) diblock copolymers reveal an extraordinary ther

173 , including polymerization of rac-lactide, L-lactide, DL-lactide, and caprolactone, followed by their

174 platform and the sirolimus-carrying poly(d,l-lactide) drug coating.

175 ot the case as a fraction incorporating meso-lactide due to racemization occurring during the synthes

176 ld enable a sequential polymerization of the lactide enantiomers to afford stereoblock copolymers wit

177 bles controlled copolymerization of OCAs and lactide, facilitating the synthesis of block copolymers

178 mately 10 to approximately 110 mug/min), and lactide from polylactic acid (PLA) filaments (ranging fr

179 disc composed of biodegradable poly-(D),(L)-lactide/glycolide copolymer.

180 LGA attributes, i.e., molecular weight (MW), lactide:glycolide (L/G) ratio, blockiness, and end group

181 LGA attributes (i.e., molecular weight (MW), lactide:glycolide (L/G) ratio, blockiness, and end group

182 ecular weight standards, and determining the lactide:glycolide (L: G) ratio by (1)H NMR and the end-g

183 ed for characterization of Glu-PLGA with the lactide:glycolide (L:G) ratio of 55:45 used in Sandostat

184 nally characterized by its molecular weight, lactide:glycolide (L:G) ratio, and end group.

185 n limited to measuring its molecular weight, lactide:glycolide (L:G) ratio, and end-group.

186 lve PLGA polymers depending on the polymer's lactide:glycolide (L:G) ratio.

187 a-butyrolactone, and D, L, meso, and racemic lactides has been studied with the PHB-depolymerase (P.

188 tion of isotactic poly(L-lactide) and poly(D-lactide) has led to improved properties compared with ea

189 in the polymerization of either meso- or rac-lactide, homochiral 4 was found to exhibit excellent ste

190 this challenge, microparticles composed of l-lactide homopolymer and l-lactide/1,3-dioxolane (co)poly

191 n a sphere (micelle) forming poly(isoprene-b-lactide) (IL) diblock copolymer melt, investigated as a

192 cticity to produce stereoblock PLA, from rac-lactide improves thermal properties but is an outstandin

193 zwitterionic ring-opening polymerization of lactide initiated by N-heterocyclic carbenes generates c

194 e copolymer poly(ethylene glycol)-b-poly(d,l-lactide) into well-defined nanotubes.

195 strially relevant bulk polymerization of rac-lactide is also demonstrated and provides key insights f

196 )Cl(-) (PPN(+)Cl(-)) selectively polymerizes lactide (L and rac) dissolved in neat propylene oxide (P

197 ol (PEG) macromers chain-extended with short lactide (L) and glycolide (G) segments were used for gra

198 g to monomer (CRM), i.e., the formation of l-lactide (l-LA) from waste plastic.

199 d reactions, including polymerization of rac-lactide, L-lactide, DL-lactide, and caprolactone, follow

200 CsA-initiated ring-opening polymerization of lactide (LA) followed by nanoprecipitation.

201 chemo- and regioselective polymerizations of lactide (LA) followed by nanoprecipitation.

202 ered to catalyze rapid epimerization of meso-lactide (LA) or LA diastereomers quantitatively into rac

203 for the ring-opening polymerization (ROP) of lactide (LA) to form poly(lactic acid) (PLA) at room tem

204 rol for the stereospecific polymerization of lactide (LA) were investigated through studies of alumin

205 olymerizations of -caprolactone (CL) and D,L-lactide (LA) were performed.

206 yclic lactone, and show that copolymers of l-lactide (LA) with small amounts of ODO have improved mec

207 of isocyanate, polymerization process for L-lactide (LA), methyl methacrylate (MMA) and dehydrosilyl

208 t block copolymerization of betaMdeltaVL and lactide leads to a new class of high-performance polyest

209 on of styrene and divinylbenzene from a poly(lactide) macro-chain transfer agent in the presence of n

210 The ring-opening polymerization of L-lactide mediated by these alcohol-bonded thioimidates yi

211 In addition, celecoxib-poly(lactide) microparticles (750 microg drug/rat) were admin

212 With celecoxib-poly(lactide) microparticles, choroid-RPE, retina, and vitreo

213 e form or orally after encapsulation in poly(lactide) microspheres, induced significant protective im

214 study indicates that insertion of the first lactide monomer into the tin(II) alkoxide bond is facile

215 ed for up to fifteen sequential additions of lactide monomer to the polymerization reaction.

216 ree iodinated monomeric moieties (a modified lactide, morpholine-2,5-dione, and caprolactone), which

217 ne) (mPEG-CL) and poly(ethylene glycol-block-lactide) (mPEG-LA) were unstable in fetal bovine serum,

218 oxy poly(ethyleneglycol)-b-poly(carbonate-co-lactide) [mPEG-b-P(CB-co-LA)] polymeric nanoparticles by

219 VEGF detection, and incorporated with poly-L-lactide nanoparticles (PLLA NPs) for signal amplificatio

220 yclooctadiene) and copolymerizing it with DL-lactide, novel polymeric alloys of PLA can be created th

221 Our previous study showed that poly(d,l-lactide) NPs conjugated with an antielastin antibody cou

222 Poly(d,l-lactide) NPs were loaded with BB-94 and conjugated with

223 Some compounds such as lactide or cyclopentanone were detected only by GC-MS wh

224 ies on self-assembly of poly(butadiene)-poly(lactide) (PB-PLA) diblock copolymers followed by selecti

225 Poly(ethylene oxide)-co-poly(d,l-lactide) (PEG-PDLA) formed micelles with elastic amorpho

226 odegradable poly(ethylene glycol)-b-poly(d,l-lactide) (PEG-PDLLA) block copolymers, with the two bloc

227 ning PLGA and poly(ethylene glycol)/poly(D,L-lactide) (PEG-PLA) blends (n = 9, P = 0.03).

228 into larger poly(ethylene glycol)-b-poly(D,L-lactide) (PEG-PLA) NPs (~70nm).

229 s cores while poly(ethylene oxide)-co-poly(l-lactide) (PEG-PLLA) formed micelles with solid crystalli

230 seed and skin were stabilized with poly-d,l-lactide (PLA) polymer by the emulsion-evaporation method

231 ug Diclofenac (DCF) in an electrospun poly-L-lactide (PLA) scaffold.

232 ), poly-epsilon-caprolactone (PCL), poly-D,L-lactide (PLA), or poly-lactide-co-glycolide (PLGA), and

233 ed bone allograft (DFDBA) (BG+PDox); poly(DL-lactide) PLA barrier without doxycycline + DFDBA (BG+P);

234 wo molecular weights (Low, High) and poly(DL-lactide) (PLA) (termed PLG-L, PLG-H, and PDLA, respectiv

235 sembled from a block copolymer of poly (D, L-lactide) (PLA) and monomethoxy polyethylene glycol (mPEG

236 as an initiator to form copolymers with poly(lactide) (PLA) and poly(epsilon-caprolactone) (PCL).

237 poly(l-lactide) (PLLA) shell and a poly(D,L-lactide) (PLA) cap that were fabricated by sequential ca

238 we sought to develop an injectable poly(D,l-lactide) (PLA) microparticle for sustained release of co

239 cells were cultured within either poly (D,L-lactide) (PLA) or a fused fiber ceramic and evaluated fo

240 ssfully applied to mixtures of cyclic poly(L-lactide) (PLA) with increasing amounts of its linear top

241 zations of selected diluents with a poly(d,l-lactide) (PLA), polydimethylsiloxane (PDMS), or polystyr

242 polymer film with composition 50:50 poly (DL-lactide) (PLA)/poly (DL-lactide-co-glycolide) (PLG) with

243 lied in the depolymerization of PET and poly(lactide), PLA.

244 e sequence PISA protocol that employs poly(l-lactide) (PLLA) as the crystallizable core-forming block

245 Poly(l-lactide) (PLLA) is the structural material of the first

246 lycolide) (PLGA) core surrounded by a poly(l-lactide) (PLLA) shell and a poly(D,L-lactide) (PLA) cap

247 O), poly(epsilon-caprolactone) (PCL), poly(L-lactide) (PLLA), and polyglycolide (PGA), with a composi

248 However, in the case of poly(l-lactide) (PLLA), arguably the most widely utilized biode

249 Poly(l-lactide) (PLLA)-based nanoparticles have attracted much

250 ionalized polyphosphoester (PPE), and poly(l-lactide) (PLLA).

251 ly to one of three treatment groups: poly(DL-lactide) polylactic acid (PLA) barrier containing 4% dox

252 These case reports suggest that a poly(DL-lactide) polymer can be used as a physical barrier with

253 yttrium alkoxides and their application for lactide polymerization are reported.

254 n, structural characterization, and detailed lactide polymerization behavior of a new Zn(II) alkoxide

255 PLA chain length in controlled solvent-free lactide polymerization combined with heavy-atom substitu

256 e oxidation state of the catalyst: selective lactide polymerization was observed in the iron(II) oxid

257 When redox reactions were carried out during lactide polymerization, catalysis could be switched off

258 complex that was completely inactive toward lactide polymerization.

259 thogonal to what was observed previously for lactide polymerization.

260 Although reactions such as oxirane and lactide polymerizations are fairly well-known now with f

261 xhibit excellent stereocontrol in a range of lactide polymerizations.

262 extremely fast for the polymerization of rac-lactide, polymerizing 500 equiv in 96% yield in less tha

263 oabsorbable membranes, made of glycolide and lactide polymers.

264 catalyst to these polyols in the presence of lactides produces well-defined triblock copolymers (PLA-

265 zed ring-opening polymerization (ROP) of rac-lactide (rac-LA).

266 e in the ring-opening of the cyclic esters L-lactide, rac-lactide, and 2,5-morpholinediones.

267 n and the ring-opening polymerization of d,l-lactide, respectively.

268 Al(OiPr)(3) produces semicrystalline poly(l-lactide) rich blocks.

269 e less reactive but do show some ability for lactide ring-enlarging.

270 , propene oxide/phthalic anhydride ROCOP and lactide ring-opening polymerization (ROP).

271 et of literature results for stereoselective lactide ring-opening polymerization, and using the algor

272 the pK(a) of [M(OH(2))(m)](n+)), whilst the lactide ROP activity and CO(2)/epoxide selectivity show

273 functional adducts were used to prepare poly(lactide)s of more complex architectures.

274 effect the stereoselective polymerization of lactides starting from a single achiral precursor and th

275 (0) = 0.84 M, [InX(3)](0)/[BnOH](0) = 1) and lactide stereoisomer (i.e., k(obs)(D,L-LA) approximately

276 cribe an approach to ordered nanoporous poly(lactide) that relies on self-assembly of poly(butadiene)

277 The ring opening polymerization of lactide, the anionic polymerization of styrene, and the

278 For lactide this is shown to form the basis for chemical amp

279 PLGA with different lactide to glycolide (50:50 and 65:35) ratios were used

280 (PLA), while rac-4 polymerizes meso- and rac-lactide to heterotactic and isotactic stereoblock PLA, r

281 LA without epimerization of the monomer, rac-lactide to heterotactic PLA (P(r) = 0.94 at 0 degrees C)

282 [(BDI-1)ZnO(i)()Pr](2) polymerized (S,S)-lactide to isotactic PLA without epimerization of the mo

283 died for the polymerization of rac- and meso-lactide to poly(lactic acid) (PLA).

284 c PLA (P(r) = 0.94 at 0 degrees C), and meso-lactide to syndiotactic PLA (P(r) = 0.76 at 0 degrees C)

285 Enantiomerically pure 4 polymerizes meso-lactide to syndiotactic poly(lactic acid) (PLA), while r

286 ntly initiate ring-opening polymerization of lactide to synthesize the diblock copolymers.

287 formed absorbable polymer barrier of poly(DL-lactide) to enhance graft containment.

288 s of poly(lactide)-b-poly(butenediol)-b-poly(lactide) triblock copolymers.

289 ators for the ring-opening polymerization of lactide under mild conditions, providing polymers with c

290 tion of an in situ formed barrier of poly(DL-lactide) used in combination with a composite graft of d

291 lute stereochemistry of ring-opening of meso-lactide using (R)-4, a polymer exchange mechanism is pro

292 sms for the ring-opening polymerization of l-lactide using a guanidine-based catalyst, the first invo

293 The polymerization of lactide using this complex proceeded with good molecular

294 ocess enhances the overall sustainability of lactide/vinyl-based copolymers and demonstrates the syne

295 the PHB-depolymerase toward propylation of L-lactide was studied.

296 A bioabsorbable polymer barrier of poly(DL-lactide) was used in conjunction with a composite graft

297 Thus, exo-6 preferentially polymerized l-lactide, whereas endo-6 preferred d-lactide as the subst

298 tyrene) and poly(trimethylsilylstyrene-block-lactide), which were thermally annealed to produce perpe

299 erization and ring-opening polymerization of lactide with DBU (1,8-diazabicyclo[5.4.0]undec-7-ene), f

300 shuttling ring-opening copolymerization of l-lactide with e-caprolactone has been achieved using two